MyMedR

Displaying all 4 publications

Abstract:

Sort:

Plant polyphenols as green sunscreen ingredients: A systematic review

Ng SY, Eh Suk VR, Gew LT

J Cosmet Dermatol, 2022 Nov;21(11):5409-5444.
PMID: 35723888 DOI: 10.1111/jocd.15170

BACKGROUND: Excessive exposure to ultraviolet radiation has harmful effects on human skin. At present, synthetic and mineral types of sunscreens used to protect against these harmful damages have been reported to cause negative health and environmental effects. The studies involving characterization and isolation of phytoconstituents from natural botanical sources are important to discover their potential beneficial effects on sunscreen development AIM: This systematic review provides specific and compiled information on the photoprotective properties of natural botanical sources for sunscreen development. The efforts in research and innovation are essential to ensure the safety and sustainability of plant-based sunscreen products.
METHODS: In this review, a total of 35 articles were selected using the Scopus database based on the inclusion and exclusion criteria RESULT: The significant correlation between total phenolic content, total flavonoid content, antioxidant activities, and sun protection factor were shown in these studies which confirmed the potential benefits of natural plants in sunscreen development.
CONCLUSIONS: In addition, natural botanical sources also exhibit excellent anti-tyrosinase, anti-aging, and anti-inflammatory activities. However, the biological activities of plants were dependent on the solvents used for extraction.
Utilization of phototherapy and treatment response in adults with psoriasis: Data from the Malaysian Psoriasis Registry

Ooi SY, Tang MM, Loo CH, Tan WC, Robinson S, Malaysian Psoriasis Registry Working Group

Photodermatol Photoimmunol Photomed, 2023 Mar;39(2):155-158.
PMID: 36692070 DOI: 10.1111/phpp.12864
Neurophysiological and imaging biomarkers of lower motor neuron dysfunction in motor neuron diseases/amyotrophic lateral sclerosis: IFCN handbook chapter

Shin-Yi Lin C, Howells J, Rutkove S, Nandedkar S, Neuwirth C, Noto YI, et al.

Clin Neurophysiol, 2024 Mar 20;162:91-120.
PMID: 38603949 DOI: 10.1016/j.clinph.2024.03.015

This chapter discusses comprehensive neurophysiological biomarkers utilised in motor neuron disease (MND) and, in particular, its commonest form, amyotrophic lateral sclerosis (ALS). These encompass the conventional techniques including nerve conduction studies (NCS), needle and high-density surface electromyography (EMG) and H-reflex studies as well as novel techniques. In the last two decades, new methods of assessing the loss of motor units in a muscle have been developed, that are more convenient than earlier methods of motor unit number estimation (MUNE),and may use either electrical stimulation (e.g. MScanFit MUNE) or voluntary activation (MUNIX). Electrical impedance myography (EIM) is another novel approach for the evaluation that relies upon the application and measurement of high-frequency, low-intensity electrical current. Nerve excitability techniques (NET) also provide insights into the function of an axon and reflect the changes in resting membrane potential, ion channel dysfunction and the structural integrity of the axon and myelin sheath. Furthermore, imaging ultrasound techniques as well as magnetic resonance imaging are capable of detecting the constituents of morphological changes in the nerve and muscle. The chapter provides a critical description of the ability of each technique to provide neurophysiological insight into the complex pathophysiology of MND/ALS. However, it is important to recognise the strengths and limitations of each approach in order to clarify utility. These neurophysiological biomarkers have demonstrated reliability, specificity and provide additional information to validate and assess lower motor neuron dysfunction. Their use has expanded the knowledge about MND/ALS and enhanced our understanding of the relationship between motor units, axons, reflexes and other neural circuits in relation to clinical features of patients with MND/ALS at different stages of the disease. Taken together, the ultimate goal is to aid early diagnosis, distinguish potential disease mimics, monitor and stage disease progression, quantify response to treatment and develop potential therapeutic interventions.
WHO implementation workshop on guidelines on procedures and data requirements for changes to approved biotherapeutic products, Seoul, Republic of Korea, 25-26 June 2019

Wadhwa M, Kang HN, Jivapaisarnpong T, WHO implementation workshop on guidelines on procedures and data requirements for changes to approved biotherapeutic products, Andalucia LR, Blades CDRZ, et al.

Biologicals, 2020 May;65:50-59.
PMID: 31959504 DOI: 10.1016/j.biologicals.2019.12.008

The first global workshop on implementation of the WHO guidelines on procedures and data requirements for changes to approved biotherapeutic products adopted by the WHO Expert Committee in 2018 was held in June 2019. The workshop participants recognized that the principles based on sound science and the potential for risk, as described in the WHO Guidelines on post-approval changes, which constitute the global standard for product life-cycle management are providing clarity and helping national regulatory authorities in establishing guidance while improving time-lines for an efficient regulation of products. Consequently, the regulatory situation for post-approval changes and guideline implementation is changing but there is a disparity between different countries. While the guidelines are gradually being implemented in some countries and also being considered in other countries, the need for regional workshops and further training on post-approval changes was a common theme reiterated by many participants. Given the complexities relating to post-approval changes in different regions/countries, there was a clear understanding among all participants that an efficient approach for product life-cycle management at a national level is needed to ensure faster availability of high standard, safe and efficacious medicines to patients as per the World Health Assembly Resolution 67.21.